On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation that he will retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. Mr. Butcher is expected to remain with the Company as a senior advisor from that date through February 26, 2027, or an earlier date (the Retirement Date), and will receive his current annual base salary of $780,000, prorated through the Retirement Date. The Company expects to enter into a Retirement Agreement with Mr. Butcher effective as of the Retirement Date, under which he will be entitled to payments and benefits materially consistent with those under the Company’s Executive Retirement Plan, 2026 Annual Bonus Plan, Long-Term Incentive Program, and equity awards granted thereunder, subject to their terms and conditions.
Original SEC Filing Text expand_more
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the Company ) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the Retirement Date ). As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date. The Company expects to enter into a Retirement Agreement with Mr. Butcher effective as of the Retirement Date, pursuant to which Mr. Butcher will be entitled to payments and benefits that are materially consistent with those Mr. Butcher is entitled to under, and subject to the terms and conditions of, the Company s Executive Retirement Plan, 2026 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 23, 2026 BOSTON SCIENTIFIC CORPORATION By: /s/ Susan Thompson Susan Thompson Vice President, Chief Corporate Counsel and Assistant Secretary
